Microalgal biofactories: a promising approach towards sustainable omega-3 fatty acid production.
Level 5 - mechanism / opinion, no new human data
Narrative review of biotechnology approaches without systematic synthesis or empirical human data (Level 5 by design analogy)
PubMed 22830315 · doi:10.1186/1475-2859-11-96
What was done
This paper presents a narrative overview of microalgal biotechnology platforms for the production of omega-3 long-chain polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It evaluates the transition from commercial heterotrophic production to autotrophic microalgal systems, links to aquaculture feed and biofuel production, and discusses metabolic engineering and selective breeding strategies to enhance lipid yields.
What was found
The abstract reports no quantitative experimental data or summary statistics. It notes qualitatively that marine microalgae serve as primary producers rich in EPA (C20:5) and DHA (C22:6), commercial production has historically utilized heterotrophic strains, and autotrophic strains are emerging as potential platforms when paired with genetic and breeding optimization.
Why it matters
Supplying omega-3 fatty acids directly from microalgae provides an alternative to harvesting marine fish stocks, supporting sustainable nutritional supplementation and aquaculture feed.
Limits
The abstract contains no quantitative metrics, specific strain yields, economic viability assessments, or systematic evaluation criteria. As a narrative review, it offers descriptive overviews rather than primary experimental results or structured meta-analytic data.
Cited by
- supports Fish do not synthesize EPA and DHA de novo in meaningful quantities, but obtain them by consuming microalgae at the base of the marine food chain.